Wells Fargo analyst Timothy Daley lowered the firm’s price target on Bio-Techne to $66 from $90 and keeps an Equal Weight rating on the shares following quarter results. The firm notes that its Equal Weight rating reflects cautious view on growth drivers, but recent moderation of enthusiasm for Bio-Techne as an enabler of biotech research boom is overblown.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TECH:
- Early notable gainers among liquid option names on November 7th
- Biotech Alert: Searches spiking for these stocks today
- Bio-Techne price target lowered to $70 from $100 at Deutsche Bank
- Bio-Techne price target lowered to $68 from $90 at Baird
- Bio-Techne price target lowered to $80 from $115 at KeyBanc